| pubmed-article:10472563 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10472563 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:10472563 | lifeskim:mentions | umls-concept:C0278590 | lld:lifeskim |
| pubmed-article:10472563 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:10472563 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10472563 | pubmed:dateCreated | 1999-10-22 | lld:pubmed |
| pubmed-article:10472563 | pubmed:abstractText | Patients (pts) with primary metastatic Ewing tumours (ET) have a poor prognosis for event free survival (EFS) compared to pts with localised disease. Following relapse the prognosis is extremely poor. Therefore these primary metastatic and relapsed pts were piloted for high dose therapy (HDT) for the last years. | lld:pubmed |
| pubmed-article:10472563 | pubmed:language | ger | lld:pubmed |
| pubmed-article:10472563 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10472563 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10472563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10472563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10472563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10472563 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10472563 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10472563 | pubmed:issn | 0300-8630 | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:FröhlichBB | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:JürgensHH | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:LadensteinRR | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:AhrensSS | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:BurdachSS | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:ZoubekAA | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:KlingebielTT | lld:pubmed |
| pubmed-article:10472563 | pubmed:author | pubmed-author:PaulussenMM | lld:pubmed |
| pubmed-article:10472563 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10472563 | pubmed:volume | 211 | lld:pubmed |
| pubmed-article:10472563 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10472563 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10472563 | pubmed:pagination | 284-90 | lld:pubmed |
| pubmed-article:10472563 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:meshHeading | pubmed-meshheading:10472563... | lld:pubmed |
| pubmed-article:10472563 | pubmed:articleTitle | [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS]. | lld:pubmed |
| pubmed-article:10472563 | pubmed:affiliation | Klinik für Pädiatrische Hämatologie und Onkologie, Westfälische Wilhelms-Universität, Münster. eicess@uni-muenster.de | lld:pubmed |
| pubmed-article:10472563 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10472563 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10472563 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:10472563 | pubmed:publicationType | Multicenter Study | lld:pubmed |
